Key facts
- It has raised $2.5M; the latest was Seed Round ($2.5M) in Jan 2025.
- Notable investors include DG Ventures, Kyoto University Innovation Capital, FASTAR, Open Network Lab, Startup Hokkaido — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Enu Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Enu Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enu Pharma
Developer of a nanosome technology designed to help doctors easily cure intractable diseases. The company's technology is made of core metals covered by an antiadhesive mixed self-assembled monolayer to avoid non-specific surface protein corona, enabling medical professionals to unlock the potential of drug discovery, development, and delivery.
- Sector
- Healthcare
- HQ
- Sapporo, Japan
- Founded
- 2019
- Employees
- 10
- Website
- enupharma.com/
- Ownership
- Privately Held (backing)
Enu Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enu Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enu Pharma in its N-PORT filings yet. We sweep new filings monthly.